Coeptis Therapeutics (COEP) and Its Peers Financial Review

Coeptis Therapeutics (NASDAQ:COEP) is one of 288 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Coeptis Therapeutics to related companies based on the strength of its earnings, valuation, dividends, institutional ownership, profitability, risk and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for Coeptis Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	0	2	0	3.00
Coeptis Therapeutics Competitors	1425	4541	11850	204	2.60

Coeptis Therapeutics presently has a consensus price target of $3.50, suggesting a potential upside of 872.22%. As a group, “Biological products, except diagnostic” companies have a potential upside of 128.21%. Given Coeptis Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Coeptis Therapeutics is more favorable than its peers.

Earnings & Valuation

This table compares Coeptis Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Coeptis Therapeutics	$80,000.00	-$21.27 million	-0.42
Coeptis Therapeutics Competitors	$555.85 million	-$35.05 million	6.49

Coeptis Therapeutics’ peers have higher revenue, but lower earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Coeptis Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-794.75%	-322.86%
Coeptis Therapeutics Competitors	-4,410.88%	-222.54%	-44.97%

Institutional and Insider Ownership

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 21.5% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Coeptis Therapeutics has a beta of -0.89, suggesting that its stock price is 189% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ peers have a beta of 1.00, suggesting that their average stock price is 0% less volatile than the S&P 500.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.